Press Releases

InVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of Directors

Published: November 12, 2019

CAMBRIDGE, Mass. (November 12, 2019) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Robert J. Rosenthal, Ph.D., to the Company’s Board of Directors, effective November 8, 2019. Dr. Rosenthal brings more than 25 years of experience to the InVivo Board as an accomplished executive and business leader in the biotechnology, therapeutics and medical device industries. With the addition of Dr. Rosenthal, InVivo’s Board has six members, five of whom are independent. “Dr. Rosenthal’s deep experience across a range of corporate functions, from corporate development and business operations, to strategic planning and capital market transactions, will be a […]

View Article
InVivo Therapeutics Provides Enrollment Update for INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury

Published: October 22, 2019

– First Five Patients Enrolled into Study, Reaching 25% Completion of Targeted Enrollment – CAMBRIDGE, Mass. (October 22, 2019) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a total of five patients have been enrolled into the INSPIRE 2.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), bringing the study to 25% completion of targeted enrollment. The first patient was enrolled into the INSPIRE 2.0 Study in May of 2019, and 14 sites are currently open for enrollment into the study. Richard […]

View Article
InVivo Therapeutics Announces Publication of CONTEMPO Registry Study Data in Peer-Reviewed Journal Spinal Cord

Published: July 16, 2019

CAMBRIDGE, Mass. (July 16, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a manuscript in the peer-reviewed journal Spinal Cord describing its CONTEMPO registry study data. The CONTEMPO registry study, part of the Company’s IDE submission for the Neuro-Spinal Scaffold™, was designed to provide comprehensive natural history benchmarks for the Neuro-Spinal Scaffold™ clinical study results. The CONTEMPO study included neurological recovery data from three registries of spinal cord injury (SCI) patients with similar baseline characteristics to those in the INSPIRE 1.0 Study. The registries included the North American Clinical Trials Network (NACTN), European Multicenter Study about Spinal […]

View Article
InVivo Therapeutics Announces Postponement of Annual Meeting

Published: July 12, 2019

CAMBRIDGE, Mass. (July 12, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has postponed its 2019 annual meeting of stockholders.  The annual meeting, which was originally scheduled for June 11, 2019, had been adjourned until July 11, 2019 at 8:00 am Eastern Time. Less than a majority of the shares of the Company’s outstanding common stock entitled to vote at the meeting were present in person or by proxy on July 11, 2019, and the Company therefore determined that a quorum did not exist.  The Company anticipates publicly announcing a new record date and the new […]

View Article
InVivo Therapeutics Announces Adjournment of Annual Meeting Scheduled to Reconvene on July 2, 2019

Published: June 14, 2019

–      Company urgently encourages stockholders to vote     – CAMBRIDGE, Mass. (June 14, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that its 2019 Annual Meeting of Stockholders, scheduled for June 11, 2019, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Annual Meeting will be reconvened July 2, 2019 to allow more opportunity for stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (SEC) on April 25, 2019. It has come to the Company’s attention that […]

View Article
InVivo Therapeutics Announces Enrollment of First Two Patients into the INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury

Published: May 29, 2019

CAMBRIDGE, Mass. (May 29, 2019) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first two patients have been enrolled into The INSPIRE 2.0 Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). “Having the first two patients enrolled into the INSPIRE 2.0 Study is a critical milestone for the company and for the spinal cord injury patient population, as there continues to be inadequate treatment options for these patients. With eight clinical sites now open for enrollment, we remain optimistic about continuing to […]

View Article
InVivo Therapeutics Announces Presentation of Twelve-Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury

Published: April 17, 2019

– E-poster Presented at the 2019 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting – CAMBRIDGE, Mass. (April 17, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) (“InVivo” or the “Company”) today announced the presentation of the twelve-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). The findings were presented at the 2019 AANS Meeting in San Diego, CA through an e-poster titled, “Twelve Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute […]

View Article
InVivo Therapeutics Reports 2018 Year-end Financial Results and Provides Business Update

Published: April 1, 2019

CAMBRIDGE, Mass. (April 1, 2019) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2018. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “InVivo achieved many critical and exciting milestones over the past year. Early in 2018 we received FDA approval of our supplemental Investigational Device Exemption (IDE) to initiate a second pivotal study of the company’s Neuro-Spinal Scaffold™ in patients with acute spinal cord injury (SCI), the INSPIRE 2.0 Study.  In addition, we successfully raised net proceeds of $16.5 million in 2018, which put us in a position to […]

View Article
InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Published: January 14, 2019

CAMBRIDGE, Mass. (Jan. 14, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announces the appointment of Richard Christopher as its Chief Financial Officer and Treasurer, effective January 14, 2019. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD, Inc., Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., […]

View Article
InVivo Therapeutics to Present at the LD Micro Main Event on Tuesday December 4th, 2018

Published: November 29, 2018

CAMBRIDGE, Mass. (November 29, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the LD Micro Main Event on Tuesday, December 4, 2018 at 7:30 am Pacific Time at the Luxe Hotel in Los Angeles, CA. Dr. Toselli’s presentation will discuss recent company updates.  A live webcast of Dr. Toselli’s presentation will be available at http://wsw.com/webcast/ldmicro15/nviv/ and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in 5-10 minutes before the event to ensure a timely connection. […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.